Reboxetine in the treatment of depression: Early clinical experience in the UK

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue 3, 1998, Pages 195-201

  Baldwin, David ^a   Hawley, Chris ^b   Szabadi, Elemer ^c   Burgess, Judith ^d   Thomson, Joan ^e   Bullock, Roger ^f   Lagnado, Max ^g  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Hertfordshire Neurosci Res Group   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d AMERSHAM HOSPITAL   (United Kingdom)

^e HAIRMYRES HOSPITAL   (United Kingdom)

^f VICTORIA HOSPITAL   (United Kingdom)

^g Pharmacia and Upjohn Ltd   (United Kingdom)

Author keywords

Depression; Functioning; Noradrenaline; Reboxetine; Retrospective survey

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEPRESSION; DRUG RESPONSE; EXPERIENCE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSYCHIATRIST; QUESTIONNAIRE; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; UNITED KINGDOM; URINARY TRACT DISEASE;

EID: 0031656623     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509809115356     Document Type: Article

References (20)

1. Preskorn HS (1994) Antidepressant drug selection. J Clin Psychiatry 55 (9, suppl A): 6-22.
2. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
3. Healy D, McMonagle T (1997) The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 11 (suppl): S25-S31.
4. Brunello N, Racagni G (1998) Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 13: S13-S19.
5. Montgomery SA (1997) Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11 (suppl): S9-S15.
6. Bosc M, Dubini A, Polin V (1997) Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 7 (suppl 1): S49-S55.
7. Mucci M (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 11 (suppl): S33-S37.
8. Dostert P, Benedetti MS, Poggesi I (1997) Review of pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7 (suppl 1): S23-S35.
9. Healy D (1997) The Antidepressant Era. Harvard University Press, Cambridge, MA.
10. Wells KB, Stewart A, Hays RD et al (1989) The functioning and well-being of depressed patients. JAMA 262: 914-9.
11. Tweed DL (1993) Depression-related impairment: estimating concurrent and lingering effects. Psychol Med 23: 373-86.
12. Versiani M (1998) The selective noradrenaline reuptake inhibitor, reboxetine, has an early onset of action. American Psychiatric Association Meeting, Toronto, June 1998, Abstract NR678.
13. Katona C (1998) Reboxetine is as effective and better tolerated than imipramine in elderly patients with depression. American Psychiatric Association Meeting, Toronto, June 1998, Abstract NR337.
14. Stassen HH, Delini-Stula A, Angst J (1993) Time course of improvement under antidepressant treatment: a survival-analytical approach. Euro Neuropsychoplmrmacol 3: 127-35.
15. Dubini A, Bosc M, Polin V (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 11 (suppl): S17-23.
16. Massana J, Moller H-J, Burrows GD et al (1998) Reboxetine: a double blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol (in press).
17. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122: 509-22.
18. Montgomery SA (1997) Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neurophyschopharmacol 7 (suppl 1): S3-S9.
19. Carlsson A, Corrodi H, Fuxe K, Hokfelt T (1969) The effects of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-metatyramine. Eur J Pharmacol 5: 357-66.
20. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1984) Drug-responsive symptoms in melancholia. Arch Gen Psychiatry 41: 663-8.